SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Momenta Pharmaceuticals Inc.
An SI Board Since March 2004
Posts SubjectMarks Bans Symbol
3027 64 0 MNTA
Emcee:  michael_f_murphy Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
2527MNTA ‘ReadMeFirst’ updated: <i>generic Lovenox now has 44% market share; DewDiligence_on_SI-10/4/2010
2526<i>Can Teva be trusted?</i> I'd say yes. Their real interest heBiomaven-10/1/2010
2525Can Teva be trusted? As a very successful generic company that has made almost tuck-9/29/2010
2524You sure did provoke a lot of response, didn't you? ;-) Some of the more rJeffry K. Smith-9/29/2010
2523Since shareholders/public peons aren't being apprised of regulatory inspectituck-9/29/2010
2522<i>It turns out that Teva's enoxaparin facilities have been inspected,Jeffry K. Smith-9/29/2010
2521If they can't prove equivalence to the point of full substitutability, I doutuck-9/29/2010
2520I replied to your post in siliconinvestor.com . Regards, DewDewDiligence_on_SI-9/29/2010
2519If they did inspect it, that is another notch towards success indeed, and I assumopgcw-9/29/2010
2518It turns out that Teva's enoxaparin facilities have been inspected, includintuck-9/29/2010
2517Agreed that this meeting has little or no consequence for MNTA in the short run.DewDiligence_on_SI-9/28/2010
2516"Approval Pathway for Biosimilar and Interchangeable Biological Products&qutuck-9/28/2010
2515MNTA ‘ReadMeFirst’ updated: <i>Copaxone is only approved MS drug with preDewDiligence_on_SI-9/28/2010
2514<i>Inequitable conduct</i> is alive and well after all—at least withDewDiligence_on_SI-9/28/2010
2513MNTA ‘ReadMeFirst’ updated: <i>despite what Teva says, US Copaxone patenDewDiligence_on_SI-9/25/2010
2512thestreet.com Maybe this meeting will finally resolve any outstanding issues...Arthur Radley-9/20/2010
2511MNTA ‘ReadMeFirst’ updated: <i>MNTA receives US patent on Lovenox charactDewDiligence_on_SI-9/19/2010
2510I suspect this is a trap<G>tom pope-9/17/2010
2509Obviously genisi is not a mover and a shaker :-)idos-9/17/2010
2508Damn. You beat me to it!tom pope-9/16/2010
2507I give, Tom. You talk in riddles. This conversation is over. >eom<Jeffry K. Smith-9/16/2010
2506I didn't say the iHub posters are the sellers.tom pope-9/16/2010
2505"The information I don't have, and would love to get my hands on, is thJeffry K. Smith-9/16/2010
2504Teva is a major phama. They say they have confidence in getting approval soon. Tewolf-9/16/2010
2503The information I don't have, and would love to get my hands on, is that whitom pope-9/16/2010
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News